Diovan CHF Claim: Use As Substitute For ACE Inhibitor Supported By FDA
Executive Summary
FDA's "approvable" letter for Diovan in congestive heart failure suggests that existing data are sufficient to approve the drug as a substitute to ACE inhibitors, Novartis Pharmaceuticals Development Head Joerg Reinhardt told an Oct. 30 New York analysts meeting
You may also be interested in...
Drug Similarities Provide Evidence Latitude, Temple Says; Diovan Example?
Pharmacologic similarity between compounds gives FDA greater latitude in the amount and type of data required for approval, Office of Medical Policy Director Robert Temple indicated during an Aug. 3 interview with "The Pink Sheet.
Drug Similarities Provide Evidence Latitude, Temple Says; Diovan Example?
Pharmacologic similarity between compounds gives FDA greater latitude in the amount and type of data required for approval, Office of Medical Policy Director Robert Temple indicated during an Aug. 3 interview with "The Pink Sheet.
Novartis Diovan Gets Heart Failure Claim But Is Second Line To ACE Inhibitors
Novartis' Diovan approval for the treatment of heart failure makes the drug the first angiotensin II receptor blocker to carry the indication, but limits it to patients who cannot take ACE inhibitors